Search results
Results from the WOW.Com Content Network
An Eli Lilly & Co. Zepbound injection pen Credit - Shelby Knowles/Bloomberg—Getty Images. W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises ...
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.. In a head-to-head comparison of the two GLP-1 drugs ...
While both medications showed a significant weight loss benefit, after 72 weeks on treatment, people treated with Zepbound lost 20% of their body weight, compared to people on Wegovy who lost just ...
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical trial, Lilly said in a release Wednesday.
They also reported that 31% of people taking Zepbound achieved at least 25% body weight loss compared to 16% for those taking Wegovy. On average, people taking Zepbound lost about 50 pounds, while ...
Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a 2023–24 randomized clinical ...
Lilly said patients taking Zepbound lost about 20% of their weight on average compared to nearly 14% for Wegovy. The drugmaker also said more patients taking Zepbound achieved at least 25% weight ...
Meanwhile, a trial of Wegovy, the version of Ozempic approved for weight loss, showed adults without diabetes who took the drug lost an average of 12.4% of their initial body weight after a year ...